Pneumococcal Polysaccharide Vaccine Market - Forecast(2021 - 2026)

Report Code: HCR 67449 Report Format: PDF + Excel (Delivery in 48 Hrs)
Pneumococcal Polysaccharide Vaccine Market Overview
Pneumococcal Polysaccharide Vaccine Market size is forecast to reach $4.2 billion by 2025, growing at a CAGR of 4.65% during the forecast period 2020-2025. Pneumococcal disease refers to any illness caused by pneumococcal bacteria (primarily Streptococcus pneumonia). Pentafluorobenzoic acid (PFBA) inhibits neutrophil phagocytosis, leading to pneumococcal survival. These bacteria can cause many types of illnesses, including pneumonia, which is an infection of the lungs.  Pneumococcal bacteria are one of the most common causes of pneumonia. The vaccine for Pneumococcal Polysaccharide, Pneumococcal polysaccharide vaccine, also known as Pneumovax 23 is the first pneumococcal vaccine derived from a capsular polysaccharide and is an important landmark in medical history. Growth of the prevalence of pneumonia across various countries of the globe, improving healthcare infrastructure and rising government focus on immunization programs for pneumonia has resulted in a rise in demand of Pneumococcal Polysaccharide Vaccine across the globe. 

Report Coverage
The report: “Pneumococcal Polysaccharide Vaccine Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Pneumococcal Polysaccharide Vaccine Market.
 
By Product Type: Prevnar 13, Synflorix, Pneumovax 23
By Dosage: Single Dose Vial, Pre-Filled Syringe
By End User: Child, Adult, Geriatric
By Route of Administration: Intravenous, Intramuscular, Subcutaneous
By Geography: North America, Europe, Asia-Pacific, Rest of the World (RoW) 

Key Takeaways
  • North America dominated the Pneumococcal Polysaccharide Vaccine Market in the year 2019 owing to increasing incidences of pneumococcal contaminations, presence of potential players that develops novel treatment and more government schemes and investments on healthcare. The Pneumococcal Polysaccharide Vaccine Market scope for different regions will be provided in the final report.
  • High prevalence rate of pneumococcal diseases, growing government investments on immunization and increasing healthcare expenditure by masses for good health have helped in significant growth of Pneumococcal Polysaccharide Vaccine Market. 
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Pneumococcal Polysaccharide Vaccine Market Research report.
  • Higher costs associated with the development of vaccines and delays of vaccine production processes is anticipated to hamper the market growth of the Pneumococcal Polysaccharide Vaccine Industry.

Produce Type - Segment Analysis
Prevnar 13 held the largest share in the product type segment of Pneumococcal Polysaccharide Vaccine Market in 2019 and is estimated to grow at a CAGR of 4.9% during the forecast period 2020-2025. Growing demand as pneumonia vaccine across various countries, approval and recommendations by WHO for its efficiency in preventing pneumonia and increasing usage for pneumonia treatment among the geriatric population have fuelled the market growth of this segment. Pneumovax 23 secured the second largest share in 2019. Primary growth of this segment is driven by price rises in the drug market and population growth. Pneumovax 23 helps protect against the most common types of pneumococcal bacteria very quickly and who are at increased risk of being infected. It is also recommended as a routine vaccination for people aged 50 years and older. Prevnar 13 is set to be the fastest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025. Pfizer has come up with its future for a next-generation vaccine. It is in the early stages of developing a pneumococcal shot that covers 20 serotypes.

End User - Segment Analysis
The geriatric population (aged 60 or more) holds the major share in the end user segment of Pneumococcal Polysaccharide Vaccine Market in 2019. Pneumonia in the elderly happens fast and the prognosis is poor, and elderly are susceptible to severe Pneumonia. The mortality rate for severe pneumonia is as high as 20%. The principal cause of the death is respiratory insufficiency. Improving government expenditure on healthcare infrastructure in developing countries like China and Japan have further helped in focus on the health of old people.  Geriatric population segment is poised to continue dominating the market with the highest CAGR during the forecast period 2020-2025. This is owing to the increase of pneumonia incidence in the geriatric population from 18% in 2019 to 23% in 2040, owing to disproportionate population growth in the oldest age groups. The fraction of outpatient pneumonia accounted for by the old age people is anticipated to increase from 2% to 4%.

Geography - Segment Analysis
North America dominates the geography segment of Pneumococcal Polysaccharide Vaccine Market with a share of more than 39.7% in 2019, followed by Europe. The increasing cases of people suffering from pneumococcal contaminations and presence of potential players that are developing novel treatment has led to gradual rise in the treatment market in this region. Ageing population and the growing healthcare investments by government along with major key players of the market has also led to growing opportunities for this market. These factors have driven the market growth in this region. Europe held the second largest share in 2019, owing to presence of a well-developed healthcare infrastructure and growing incidences of pneumonia among the aged population of this region.
Asia-Pacific is estimated to grow at the fastest rate at a higher CAGR during the forecast period 2020-2025. The World Health Organization (WHO) has estimated an incidence of 0.37 episodes per child per year for clinical pneumonia, India accounts for 36% of the total cases, WHO South East Asia regional burden. Approximately 10 to 20% of these episodes tend to be severe. Also, there is a rapid entry of key market players in this region and launch of new market products of Pneumonia Polysaccharide Vaccines, which is poised to provide greater opportunities in the upcoming years.

Drivers – Pneumococcal Polysaccharide Vaccine Market

  • High prevalence rate of pneumococcal diseases
Incidence rates were higher in subjects ≥85 years of age (3507 per 100,000 population) compared with those 65–74 years old (662 per 100,000). Pneumococcal pneumonia accounted for 20.6 % (13.9–27.3 %) of hospitalizations, with an incidence of 274 per 100,000 population As a result, the Pneumococcal Polysaccharide Vaccine Market is set to witness an upsurge in recent years.

  • Government support in creating awareness regarding pneumonia immunization programs
The Society of Healthcare Epidemiology of America and Infectious Diseases Society of America developed the guidelines for strategies to prevent ventilator-associated pneumonia in acute care hospitals. In addition, various organizations across countries are putting in investments for pneumonia prevention.

Challenges – Pneumococcal Polysaccharide Vaccine Market

  • Delays of vaccine production processes
PPSV23 contains polysaccharide antigen from 23 types of pneumococcal bacteria. It contains 25 µg of each antigen per dose and contains 0.25% phenol as a preservative. At a time when demand is high, longer time for production causes service delay and causes a restraint in the demand. This is anticipated to hamper the market growth in the forecast period 2020-2025.

Pneumococcal Polysaccharide Vaccine Market Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Pneumococcal Polysaccharide Vaccine Market. Pneumococcal Polysaccharide Vaccine Market revenue is primarily generated by manufacturing and distribution by the key market players. In 2019, Pneumococcal Polysaccharide Vaccine Market share is consolidated by the top players present in the market. Pneumococcal Polysaccharide Vaccine Market top 10 companies are Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc, Sanofi Pasteur, China National Biotec Group, Astellas Pharma Inc., Serum Institue of India Ltd, SK bioscience, Walvax Biotechnology Co., Ltd and Beijing Minhai Biotechnology Co., Ltd among others.

Acquisitions/Product Launches
  • In September 2019, Pfizer announced positive preliminary results from a proof-of-concept phase 2 study (B7471003) of its 20-valent pneumococcal conjugate vaccine candidate being investigated for the prevention of invasive disease and otitis media in healthy infants.
  • In June 2017, GSK received World Health Organization Prequalification for Synflorix pneumococcal vaccine four-dose vial.
  • In February 2019, Astellas and Affinivax's novel pneumococcal vaccine entered the human testing stage.

1. Pneumococcal Polysaccharide Vaccine Market Overview
    1.1 Definitions and Scope
2. Pneumococcal Polysaccharide Vaccine Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Product Type
    2.3 Key trends by End User
    2.4 Key trends by Geography
3. Pneumococcal Polysaccharide Vaccine Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Pneumococcal Polysaccharide Vaccine Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Pneumococcal Polysaccharide Vaccine Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Pneumococcal Polysaccharide Vaccine Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Pneumococcal Polysaccharide Vaccine Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Pneumococcal Polysaccharide Vaccine Market – By Product Type (Market Size –$Million/$Billion)
    8.1 Prevnar 13
    8.2 Synflorix
    8.3 Pneumovax 23
9. Pneumococcal Polysaccharide Vaccine Market – By Dosage (Market Size –$Million/$Billion)
    9.1 Single Dose Vial
    9.2 Pre-Filled Syringe
10. Pneumococcal Polysaccharide Vaccine Market – By End User (Market Size –$Million/$Billion)
    10.1 Child
    10.2 Adult
    10.3 Geriatric
11. Pneumococcal Polysaccharide Vaccine Market – By Route of Administration (Market Size –$Million/$Billion)
    11.1 Intravenous
    11.2 Intramuscular
    11.3 Subcutaneous
12. Pneumococcal Polysaccharide Vaccine Market - By Geography (Market Size –$Million/$Billion)
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 Rest of the World
        12.4.1 Middle-East 
        12.4.2 Africa
        12.4.3 South America
13. Pneumococcal Polysaccharide Vaccine Market - Entropy
14. Pneumococcal Polysaccharide Vaccine Market – Industry/Segment Competition Landscape (Premium) 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
        14.1.4 Best Practices for Companies
15. Pneumococcal Polysaccharide Vaccine Market – Key Company List by Country Premium (Premium)
16. Pneumococcal Polysaccharide Vaccine Market Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Global Pneumococcal Polysaccharide Vaccine Market, By Dosage Market 2019-2024 ($M)
1.1 Single Dose Vial Market 2019-2024 ($M) - Global Industry Research
1.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
1.2 Pre-Filled Syringe Market 2019-2024 ($M) - Global Industry Research
2.Global Global Pneumococcal Polysaccharide Vaccine Market, By End User Market 2019-2024 ($M)
2.1 Child Market 2019-2024 ($M) - Global Industry Research
2.2 Adult Market 2019-2024 ($M) - Global Industry Research
2.3 Geriatric Market 2019-2024 ($M) - Global Industry Research
3.Global Global Pneumococcal Polysaccharide Vaccine Market, By Dosage Market 2019-2024 (Volume/Units)
3.1 Single Dose Vial Market 2019-2024 (Volume/Units) - Global Industry Research
3.1.1 Key Growth Factor And Opportunity Market 2019-2024 (Volume/Units)
3.2 Pre-Filled Syringe Market 2019-2024 (Volume/Units) - Global Industry Research
4.Global Global Pneumococcal Polysaccharide Vaccine Market, By End User Market 2019-2024 (Volume/Units)
4.1 Child Market 2019-2024 (Volume/Units) - Global Industry Research
4.2 Adult Market 2019-2024 (Volume/Units) - Global Industry Research
4.3 Geriatric Market 2019-2024 (Volume/Units) - Global Industry Research
5.North America Global Pneumococcal Polysaccharide Vaccine Market, By Dosage Market 2019-2024 ($M)
5.1 Single Dose Vial Market 2019-2024 ($M) - Regional Industry Research
5.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
5.2 Pre-Filled Syringe Market 2019-2024 ($M) - Regional Industry Research
6.North America Global Pneumococcal Polysaccharide Vaccine Market, By End User Market 2019-2024 ($M)
6.1 Child Market 2019-2024 ($M) - Regional Industry Research
6.2 Adult Market 2019-2024 ($M) - Regional Industry Research
6.3 Geriatric Market 2019-2024 ($M) - Regional Industry Research
7.South America Global Pneumococcal Polysaccharide Vaccine Market, By Dosage Market 2019-2024 ($M)
7.1 Single Dose Vial Market 2019-2024 ($M) - Regional Industry Research
7.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
7.2 Pre-Filled Syringe Market 2019-2024 ($M) - Regional Industry Research
8.South America Global Pneumococcal Polysaccharide Vaccine Market, By End User Market 2019-2024 ($M)
8.1 Child Market 2019-2024 ($M) - Regional Industry Research
8.2 Adult Market 2019-2024 ($M) - Regional Industry Research
8.3 Geriatric Market 2019-2024 ($M) - Regional Industry Research
9.Europe Global Pneumococcal Polysaccharide Vaccine Market, By Dosage Market 2019-2024 ($M)
9.1 Single Dose Vial Market 2019-2024 ($M) - Regional Industry Research
9.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
9.2 Pre-Filled Syringe Market 2019-2024 ($M) - Regional Industry Research
10.Europe Global Pneumococcal Polysaccharide Vaccine Market, By End User Market 2019-2024 ($M)
10.1 Child Market 2019-2024 ($M) - Regional Industry Research
10.2 Adult Market 2019-2024 ($M) - Regional Industry Research
10.3 Geriatric Market 2019-2024 ($M) - Regional Industry Research
11.APAC Global Pneumococcal Polysaccharide Vaccine Market, By Dosage Market 2019-2024 ($M)
11.1 Single Dose Vial Market 2019-2024 ($M) - Regional Industry Research
11.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
11.2 Pre-Filled Syringe Market 2019-2024 ($M) - Regional Industry Research
12.APAC Global Pneumococcal Polysaccharide Vaccine Market, By End User Market 2019-2024 ($M)
12.1 Child Market 2019-2024 ($M) - Regional Industry Research
12.2 Adult Market 2019-2024 ($M) - Regional Industry Research
12.3 Geriatric Market 2019-2024 ($M) - Regional Industry Research
13.MENA Global Pneumococcal Polysaccharide Vaccine Market, By Dosage Market 2019-2024 ($M)
13.1 Single Dose Vial Market 2019-2024 ($M) - Regional Industry Research
13.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
13.2 Pre-Filled Syringe Market 2019-2024 ($M) - Regional Industry Research
14.MENA Global Pneumococcal Polysaccharide Vaccine Market, By End User Market 2019-2024 ($M)
14.1 Child Market 2019-2024 ($M) - Regional Industry Research
14.2 Adult Market 2019-2024 ($M) - Regional Industry Research
14.3 Geriatric Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
2.Canada Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
3.Mexico Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
4.Brazil Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
5.Argentina Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
6.Peru Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
7.Colombia Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
8.Chile Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
9.Rest of South America Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
10.UK Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
11.Germany Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
12.France Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
13.Italy Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
14.Spain Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
15.Rest of Europe Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
16.China Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
17.India Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
18.Japan Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
19.South Korea Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
20.South Africa Pneumococcal Polysaccharide Vaccine Market Revenue, 2019-2024 ($M)
21.North America Pneumococcal Polysaccharide Vaccine By Application
22.South America Pneumococcal Polysaccharide Vaccine By Application
23.Europe Pneumococcal Polysaccharide Vaccine By Application
24.APAC Pneumococcal Polysaccharide Vaccine By Application
25.MENA Pneumococcal Polysaccharide Vaccine By Application
26.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Sanofi Pasteur, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.National Biotec Group, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Astellas Pharma Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Serum Institute Of Pvt Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)